Organovo and Tarveda Therapeutics Announce Definitive Merger Agreement
Organovo Holdings, Inc. (ONVO)
NASDAQ:AMEX Investor Relations:
organovo.com/about/contact/investor-relations
Company Research
Source: Business Wire
Combined company to operate as Tarveda Therapeutics upon closing of mergerTransaction to advance Tarveda’s proprietary Pentarin® miniature drug conjugates including its two clinical programs for the treatment of solid tumor malignanciesCompanies to host conference call today at 8:30 AM ET SAN DIEGO & WATERTOWN, Mass.--(BUSINESS WIRE)--Organovo Holdings, Inc. (“Organovo”) (Nasdaq: ONVO) and Tarveda Therapeutics, Inc. (“Tarveda”), a privately-held, clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin miniature drug conjugates, today announced that they have entered into a definitive merger agreement under which Tarveda would merge with a wholly-owned subsidiary of Organovo in an all-stock transaction. Upon completion of the merger, the merged company would operate under the name Tarveda Therapeutics, Inc. and trade on the Nasdaq Stock Market LLC under the ticker symbol “TVDA.”This press re
Show less
Read more
Impact Snapshot
Event Time:
ONVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ONVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ONVO alerts
High impacting Organovo Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
ONVO
News
- Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting [Yahoo! Finance]Yahoo! Finance
- Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver MeetingGlobeNewswire
- Organovo Holdings, Inc. (NASDAQ: ONVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Global Organoids Market to Surge Significantly at a CAGR of ~14% by 2030 | DelveInsight [Yahoo! Finance]Yahoo! Finance
- Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases [Yahoo! Finance]Yahoo! Finance
ONVO
Sec Filings
- 11/14/24 - Form SC
- 11/8/24 - Form 10-Q
- 10/25/24 - Form S-1
- ONVO's page on the SEC website